Johor forest city also eyeing a gambling licence for a better survival, Rumour out many weeks ago. Hopefully, the casino licence can pass it to Johor government

Sarawak has a hill top resorts repossessed from Country height @Lee Kim Yew and it's state Government is eyeing a gambling licence from federal government but until now has no news ,,,, may be Genting licence from Pahang can be used in Sarawak then.

hahaha, let TTB @Tan Tua Poa no face

yes, that is why i said they will be the witness of MACC rather than be the accused.

1st layer is 1bestarinet, seems targeted Muhideen but final target is Mamakutty....
remember privatised of power supply was objected by ex-TNB Chairman but bullzosed by Mamakutty. ther must have a lot of hanky panky, monkey business....
Now Yeoh family has to protect their family interest, to the extend of avoid going to jail, will be the forced to become witness of MACC for accusing abused of power by Mamakutty

This move is targeted Mahathir by forcing YTLpower discloses how it secured its privatisation of electric supply from TNB at a lopsided price even though its Chairman total objected such deal, but bulldozed by Mahathir when he was the PM.

Just notice ex-broker Chua Ma Yu , once one of the bosses of brokering firm, Rashid & Chua & Co, has increased his holding of 8,460,000 shares. Currently he holds 32,470,000 shares. He is number 6th major shareholders of Genting Bhd

Reasons why Closed Funds IPO collapsed and because illiquid and only benefited to the fund managers the most

https://finance.yahoo.com/news/bill-ackmans-ipo-dream-goes-173800872.html

https://www.youtube.com/watch?v=bMWfkscRsF0&t=13s

全球首款失智药Lecanemab 英核准上市开全欧先例 https://www.chinapress.com.my?p=4072020

Genting Malaysia
Higher tourist arrivals likely lifted 2Q24F
■ We expect GENM’s Malaysian operations to post qoq and yoy improvements
in 2Q24F following strong tourism data, especially in Chinese tourist arrivals.
■ Improved economic activity and tourism recovery should continue to drive
GENM earnings growth throughout FY24F, in our view.
■ GENM is our top pick for exposure to a rebound in tourism. We believe its
valuation is undemanding at 13.0x CY24F P/E with a c.6-7% dividend yield.

2Q24F likely strong from tourist arrivals boost at RWG
Genting Malaysia (GENM) will be reporting its 2Q24F results on 29 Aug 2024F. We expect
GENM’s Malaysian operations to post qoq and yoy improvements in 2Q24F revenue and
EBITDA, following tourism data indicating that total tourist arrivals in Malaysia in 2Q24 rose
26% yoy and 3% qoq to 6.0m (Fig 1). This was mainly led by healthy recovery in Chinese
tourist arrivals in Malaysia, with 2Q24 arrivals of 690k much stronger than the 320k arrivals
in 4Q23 (Fig 2). Tourist arrivals from Singapore, Indonesia and India also increased, up
10%, 25% and 87% yoy, respectively, in 2Q24, according to Tourism Malaysia. We believe
increased tourist arrivals helped drive business volumes at its gaming and non-gaming
operations in Resorts World Genting (RWG), likely contributing to GENM’s revenue growth
in 2Q24F. Disclosures from the New York State Gaming Commission also indicate that
total gross gaming revenue (GGR) from its US operations rose 3.1% yoy and 2.0% qoq in
the quarter (Fig 4). We believe this should have led to better performance from its US
operations in 2Q24, which historically contributed c.18-20% of GENM’s revenue.
Consumption and tourism growth to support GENM revenue growth
We believe improved policy direction by the Malaysia government will be positive for
economic growth in 2024F, with CGSI Research’s economics team forecasting 2024F real
GDP growth of 4.6% yoy and private consumption growth of 6.5%. Further, in 2024F, the
Ministry of Tourism, Arts, and Culture anticipates tourist arrivals in Malaysia to reach 27.3m
(2023: 20.1m), with an expected income of RM102.7bn (2023: RM71.3bn). Aside from the
positive catalysts above, we see cash handouts to lower income households in 2H24F,
higher civil servant salaries from 2025F and Employees’ Provident Fund Account 3
withdrawals as incrementally positive for GENM’s revenue growth over the next 12 months.
Reiterate Add with an unchanged SOP-based TP of RM4.00
We retain our Add call on GENM, as we expect a robust 3-year EPS CAGR of 42% in
FY22-25F, and SOP-based TP of RM4.00 (Fig 6). At the current share price, GENM is
trading at 13.0x CY24F P/E, 1.4 s.d. below its historical pre-Covid-19 mean P/E of 18x.
While there are concerns over the Nevada gaming regulator filing complaints against
Resorts World Las Vegas, run by GENM's parent company Genting Berhad, which could
affect GENM's bid for a downstate casino licence in New York, we have not factored in any
potential upside from its New York casino bid and only include GENM's land at book value
in our TP. Key re-rating catalysts are stronger-than-expected Malaysian operations and
better-than-expected operating margins. Downside risks are higher-than-expected
operating costs and slower Malaysia gaming revenue recovery.

that will be 2028, about 4 years later. GENM Priced in now?

In Singapore situation, a Casino blacklists or name requested by gamblers closed relatives

Please don't spread fear! For banks and casinos, money laundering is a norm and unavoidable , the most likely penalty is a fine and i don't think to such extend of hang licence. Recently,It happened in Singapore Genting Casino as well, it got a warning and fine,

Just came back from a routine morning walk in the garden, see a lots of same guys still stick in this forum . well I guess price will not go far at the moment.

Good, long term capital gain + dividend

Aiyo, what TuaPoaTTB's saying can be trusted 'Sai" can also be eaten.

https://klse.i3investor.com/web/blog/detail/DoubleSwords/2024-07-30-story-h-155916143

https://www.youtube.com/watch?v=fFFPrEiskjc

https://www.youtube.com/watch?v=FH3M_7W9o84&t=572s

Will recent high court decision on 4D and Sports TOTO be a catalyst for Genting?

https://www.youtube.com/watch?v=A-yVjAHulP0&t=122s
Genting day tripper

不严重,没事

https://www.youtube.com/watch?v=YOsBiOFU1dM

Pinky, can keep your Genting shares in cold storage and ignore the noise while enjoy good dividend

Yes, its dividend yield is more or less equivalent to local banks FD, high NTA, many catalysts is coming ! don't see much shorting for this counter. just have to wait....

i was doing reverse what you were doing, I bought more Singapore Banks then and will keep for dividend

Micheal2024 if that is the case, you have suffered Forex loss of S$ vs M$ 3.05 to 3.48 which is about 15%

Confirm price will be 0 " Zero", free for everyone who read this forum

Icng123@, Yes, hopefully this corporate exercise announce and implement soonest possible!

https://www.youtube.com/watch?v=kUG67at6rQQ

MichealChan 2024?

Ideal banks should take care on risk factors and quality of loan rather than high dividend payout. PBB pays more or less 50% is ideal. Reserve 50% for expansion and unseen event or circumstance happens. I checked the pattern of how 3 local Singapore Banks are running, more or less the same!

sabar sabar！ 忍耐， 忍耐！

ipo above $5 , since then diarrhea

It appears KYY not in the Top 30 shareholders as well

https://www.sinchew.com.my/?p=5554107
怎么那么快，不用下標的吗？

@Icng123 around 2013 share price above $2.20 less Dividend , around $2.05-$2.1 ?

Also make bursa vibrancy!

@AngTayKor, me, not good in trading, so can't aim like what you said "immediately buy, immediately huat"

Nibble it slowly in its down trend , hope for the best as other counters in Bursa has moved while this one remains stagnant.

Dividend receive can be enjoyed right now while capital gain by holding it can pass it to next generation. Best fit for estate planning

This one better than KSL , strong NTA to catch up and giving 5.6% dividend yield for immediate purchase!

share price moves ahead of unlocking value of assets held

For rich family with landed and plantation properties, just let the Co auto pilot for a decades also can continues growing their wealth

@ micheal 志在必得！

As at 14-3-23 net short position for GENM 21m while zero for Genting

VALUATION/RECOMMENDATION
• As TauRx is approaching a new milestone with potential commercialisation in future,
we now impute a 10% option value of TauRx’s initial IPO valuations of US$15b into our
target price, which translates into 35 sen/share. We deem this reasonable as TauRx is
submitting HMTM for regulatory approval soon.
• Maintain BUY with higher target price of RM6.13 (from RM5.78), which implies 6.5x
2024F EV/EBITDA and 0.7x 2024F P/B. In a blue-sky scenario, target price will be RM9.32 if
we fully factor in TauRx’s potential monetisation value.

- For the US, a New Drug Application (NDA) will be submitted to the Food and Drug
Administration (FDA) to review. Normally, the FDA is allotted 10 months to review new
drugs, while under priority review, that time is shortened to six months. - For the UK, we expect TauRx to seek approval via the Innovative Licencing and Access
Pathway (ILAP). Recall that in 2022, TauRx received an innovation passport from the UK’s
regulatory agency MHRA.The Innovation Passport is the first stage of the Innovative
Licensing and Access Pathway (ILAP). After attending an ILAP meeting within 4-6 weeks
of application, opinion will be received within another four weeks. - For other regions, we understand that TauRx’s subsidiary – Poredeen Limited – has
appointed and given ICB Medical the exclusive rights to manage the importation and
logistics for the HMTM drugs in Hong Kong and Macau, where qualified prescribing
doctors can request HMTM drugs on behalf of eligible patients. However, HMTM drugs are
not commercially sold there yet. Poredeen will also be meeting and submitting data
packages to other drug regulators in more territories, including China.

TauRx is a wild card for GENT, if commercialisation materialises. If TauRx secures
approval from key regulators and its HMTM drugs are commercially rolled out, the group
may be re-looking at an IPO. To recall, TauRx was initially eyeing a Nasdaq IPO in 2017
(with a potential valuation of US$15b), according to Wall Street Journal in Dec 15. If so, we
acknowledge that GENT’s 20.3% stake in TauRx could be translated to RM3.54/share
(e.RM4.50/US$1) or c.71% of its current market cap.
• Downside fairly limited if TauRx remains in limbo or does not work out. Even without
the TauRx factor, GENT’s investment merits remain appealing as the group is on track to
chart above pre-pandemic earnings dynamic in 2024-25, based on the booming tourism
scene and plenty of event catalysts from subsidiaries GENM and GENS. Furthermore, as
GENT’s valuations remain significantly below pre-pandemic levels with undervalued financial
matrixes, the group may not encounter a steep selldown in a scenario that TauRx
disappoints.

Uobkayhian latest report on Genting
Genting (GENT MK)

TauRx’s Positive Discovery A Potential Wild Card
TauRx’s convincing 24-month Phase 3 clinical trial data for its Alzheimer’s HMTM drug
may be the missing puzzle piece for regulatory approval, and could eventually unlock
deep value in GENT’s investment. On hindsight, the procedure for HTMTM securing
approval and commercial rollout may be lengthy. That said, even without the TauRx
factor, GENT trades at a cheap valuation with plenty of re-rating catalysts, Maintain
BUY with a higher target price of RM6.13 as we partially impute TauRx’s option value.